News & Views

July 8, 2020

Covid-19 Treatment Strategies

Posted By: TreehillPartners
In: Drug Development

There are two predominantly emerging therapeutic strategies for the development of drugs to treat patients with COVID-19. The first is to target the virus (SARS-CoV2) itself. This is how Remdesivir, the most widely discussed treatment for COVID-19 works. The second therapeutic strategy is to mitigate the effect of cytokine...

March 25, 2026

Will Biotech Still Be Relevant in 2030? – Treehill on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

March 24, 2026

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

March 5, 2026

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

February 23, 2026

Scrip Asks – What Does 2026 Hold For Biopharma

Posted By: TreehillPartners
In: Leadership & Restructuring

February 19, 2026

Riding the Gene Therapy Rollercoaster into 2026 – Treehill CEO in Inside Precision Medicine

Posted By: TreehillPartners
In: Drug Development

June 4, 2020

All Great Changes are Preceded by Chaos

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

The world of healthcare has been turned upside down. The COVID-19 pandemic has taken healthcare systems across the globe to breaking point, with hospitalization rates never before seen and hundreds of thousands of fatalities. While the immediate crisis was characterized by lack of personal protective equipment...

February 9, 2026

Treehill Partners Featured in Cell & Gene Therapy Review’s 2026 Industry Predictions

Posted By: TreehillPartners
In: Drug Development

January 22, 2026

Oncology Investment – Treehill in Mergermarket

Posted By: TreehillPartners
In: Dealmaking

January 19, 2026

Scrip Asks – What Does 2026 Hold For Biopharma – Part 2

Posted By: TreehillPartners
In: Dealmaking, Drug Development

January 13, 2026

Clinical Trial Partners: Sink or Swim (JPM 2026 Series, Episode 2) – Treehill Partners on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

Posted By: TreehillPartners
In: Drug Development

May 6, 2020

A Ladder with a Rung Missing

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

Drug development is like climbing a well-defined heavily regulated “ladder”. This ladder has and will always rightly hold the safety of patients subjected to experimental therapies as its number one priority. Each of the steps are clearly defined, and whilst some may intertwine generally include..

January 9, 2026

Scrip Asks – What does 2026 hold for Biopharma? Part 1

Posted By: TreehillPartners
In: Dealmaking

November 20, 2025

London Life Sciences Week – In-Depth Interview

Posted By: TreehillPartners
In: Drug Development

November 19, 2025

Manufacturing Flexibility

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

November 14, 2025

Treehill Partners Featured in FirstWord ExpertViews: The Convergence of Pharma and Biotech

Posted By: TreehillPartners
In: Strategy & Corporate Development

November 3, 2025

Pharma’s Path Through Industry Turbulence

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

April 30, 2020

Doctor Founder Ventures – Biotech Entrepreneurship Essentials

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

By the very nature of the profession, doctors become “good doctors” by developing strong entrepreneurship qualities. Running an own private practice or being part of a large group practice, each provides for taking on sizable risk and executing resource allocation tasks where one must embody strong communication qualities to see positive outcomes...

October 23, 2025

Neurology M&A – Treehill Quotes in Endpoints News

Posted By: TreehillPartners
In: Dealmaking

October 1, 2025

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

September 30, 2025

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

September 11, 2025

Keep the Patients in Mind

Posted By: TreehillPartners
In: Leadership & Restructuring

September 5, 2025

Navigating Biotech’s Perfect Storm: Pharmaphorum Podcast

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

April 9, 2020

A Forced Transition

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

Running a healthy efficient business is a full-time task for senior management during normal times. The unprecedented transition into a world of uncertainty, paired with unclear timing and nature of recovery, present not only new challenges to navigate but also an unprecedented volume of forced “restructuring” in our industry...

August 22, 2025

Optimizing Biomanufacturing

Posted By: TreehillPartners
In: Drug Development

August 16, 2025

The Biotech Funding Model Needs a Major Overhaul

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

July 24, 2025

When VC Steps Back: Finding Alternative Biotech Funding

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

July 21, 2025

“We’re making the same mistakes over and over”

Posted By: TreehillPartners
In: Did you know?, Drug Development

July 21, 2025

Can Europe take the lead on biotech?

Posted By: TreehillPartners
In: Did you know?

Subscribe to our mailings!

Navigating Biotech’s Perfect Storm: Pharmaphorum Podcast

Ali Pashazadeh, Treehill Partners CEO, recently joined Pharmaphorum’s podcast to discuss the unprecedented challenges facing biotech — and why this “perfect storm” may ultimately strengthen

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.